Supernus Pharm (SUPN) Stock Price, Quote & News

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the mon...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 301 838 2500

Website: www.supernus.com

Address:

9715 Key West Avenue, Rockville, United States

Doozio Mar. 5 at 2:49 PM

$SUPN thing about final Thursday 🐑 🎁s. 🐒🍌🧠⏰♾️

0 · Reply

Doozio Mar. 5 at 2:41 AM

$SUPN thing about chop chop huckleberries n it gets $LGND ary thru da $$$ patterns 🐒🍌🧠⏰♾️

0 · Reply

OfficialStocktwitsUser Mar. 4 at 3:01 PM

$SUPN RSI: 60.65, MACD: 1.3665 Vol: 2.22, MA20: 52.18, MA50: 50.95 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

d_risk Mar. 3 at 5:28 PM

$SUPN - Supernus Pharmaceuticals Inc - 10K - Updated Risk Factors SUPN’s risk profile tightens around ZURZUVAE commercialization and post‑marketing obligations, ONAPGO supply constraints and rising competition (e.g., AbbVie’s Vyalev), heavier reliance on third‑party partners/suppliers, expanding acquisition and goodwill risk, escalating healthcare pricing/regulatory uncertainty (including new Executive Orders and Chevron reversal), and growing patent, litigation, product liability, and cybersecurity exposures. #PharmaceuticalIndustry #ProductCommercialization #SupplyChainRisk #HealthcareRegulation #PatentLitigation 🟢 Added 🟠 Removed https://d-risk.ai/SUPN/10-K/2026-03-02

0 · Reply

txbondman Feb. 25 at 3:09 PM

sld some winners (partial) to take profits. sld $CIEN for a 640% gain; sld $SUPN for a 150% gain;

1 · Reply

Estimize Feb. 25 at 3:01 PM

Wall St is expecting 0.45 EPS for $SUPN Q1 [Reporting 05/12 AMC] http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_co

0 · Reply

Estimize Feb. 25 at 11:03 AM

$SUPN reported 0.85 EPS and 211.57 revenue for Q4. http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_content=SUPN&utm

0 · Reply

StocktwitsEarnings Feb. 24 at 9:22 PM

$SUPN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.07 down -125.00% YoY • Reported revenue of $211.57M up 21.48% YoY • Supernus Pharmaceuticals provided full year 2026 guidance for total revenues of $840M to $870M, operating earnings of $0 to $30M, and adjusted operating earnings of $140M to $170M.

0 · Reply

Doozio Feb. 24 at 8:57 PM

$SUPN thing about eps gap goes during 🐒🍌🧠⏰♾️?

0 · Reply

kshonstocks Feb. 24 at 7:38 PM

fine volume bar on $SUPN

0 · Reply

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Feb 25, 2026, 4:27 AM EST - 20 days ago

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:05 PM EST - 21 days ago

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 6:15 PM EST - 21 days ago

Supernus Pharmaceuticals to Participate in March Investor Conferences

Feb 12, 2026, 4:35 PM EST - 4 weeks ago

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

Feb 9, 2026, 11:14 AM EST - 5 weeks ago

Lunai Bioworks, Inc. Issues Letter to Shareholders

Feb 1, 2026, 7:59 AM EST - 6 weeks ago

Supernus: Outlook For 2026 Positive, Upholding Buy Rating

Jan 15, 2026, 10:31 AM EST - 2 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Dec 8, 2025, 3:57 PM EST - 3 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Dec 3, 2025, 4:05 PM EST - 3 months ago

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

Nov 21, 2025, 4:06 PM EST - 4 months ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 4:05 PM EST - 4 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Nov 5, 2025, 12:36 AM EST - 4 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 4 months ago

Supernus Announces Third Quarter 2025 Financial Results

Oct 21, 2025, 5:00 PM EDT - 5 months ago

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Sep 17, 2025, 4:05 PM EDT - 6 months ago

Supernus Pharmaceuticals: Heading In The Right Direction

Aug 27, 2025, 4:15 PM EDT - 7 months ago

Supernus Pharmaceuticals to Participate in September Investor Conferences

Aug 5, 2025, 6:18 PM EDT - 8 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Supernus Announces Second Quarter 2025 Financial Results

Jul 31, 2025, 8:44 AM EDT - 8 months ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Jul 28, 2025, 8:25 AM EDT - 8 months ago

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Jul 22, 2025, 4:30 PM EDT - 8 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

Jul 14, 2025, 4:25 PM EDT - 8 months ago

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SAGE

Jun 16, 2025, 5:31 PM EDT - 9 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

SAGE

Jun 16, 2025, 7:14 AM EDT - 9 months ago

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

SAGE

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

May 29, 2025, 8:30 AM EDT - 10 months ago

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

May 28, 2025, 4:05 PM EDT - 10 months ago

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025, 4:05 PM EDT - 10 months ago

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 10:55 PM EDT - 11 months ago

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:08 PM EDT - 11 months ago

Supernus Announces First Quarter 2025 Financial Results

Apr 23, 2025, 5:14 PM EDT - 11 months ago

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

Doozio Mar. 5 at 2:49 PM

$SUPN thing about final Thursday 🐑 🎁s. 🐒🍌🧠⏰♾️

0 · Reply

Doozio Mar. 5 at 2:41 AM

$SUPN thing about chop chop huckleberries n it gets $LGND ary thru da $$$ patterns 🐒🍌🧠⏰♾️

0 · Reply

OfficialStocktwitsUser Mar. 4 at 3:01 PM

0 · Reply

d_risk Mar. 3 at 5:28 PM

0 · Reply

txbondman Feb. 25 at 3:09 PM

sld some winners (partial) to take profits. sld $CIEN for a 640% gain; sld $SUPN for a 150% gain;

1 · Reply

Estimize Feb. 25 at 3:01 PM

Wall St is expecting 0.45 EPS for $SUPN Q1 [Reporting 05/12 AMC] http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_co

0 · Reply

Estimize Feb. 25 at 11:03 AM

$SUPN reported 0.85 EPS and 211.57 revenue for Q4. http://www.estimize.com/intro/supn?chart=historical&metric_name=eps&utm_content=SUPN&utm

0 · Reply

StocktwitsEarnings Feb. 24 at 9:22 PM

0 · Reply

Doozio Feb. 24 at 8:57 PM

$SUPN thing about eps gap goes during 🐒🍌🧠⏰♾️?

0 · Reply

kshonstocks Feb. 24 at 7:38 PM

fine volume bar on $SUPN

0 · Reply

ortega1963 Feb. 20 at 6:31 AM

$SUPN ascending Triangle

0 · Reply

NetworkNewsWire Feb. 17 at 2:05 PM

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A $OTLC $ARWR $MGTX $SUPN $JNJ https://ibn.fm/8zb4f

1 · Reply

Night_Owl_Biotech Feb. 6 at 2:23 AM

Of the 63 commercial-stage non-oncology focused bios with market caps ranging from $750MM to $15B, only 8 are trading higher after the worst 2 days for the XBI since April 2025. $OCUL was up we suspect due to renewed hope for a Sanofi buyout. Recall Sanofi offered $16 per share to acquire OCUL last September. OCUL closed today (6 months later) at $8.91. $SUPN has been quiet (no PR since November) but perhaps SUPN's gains reflect the virtue of diversity. $TWST released Q126 financials Monday after the close. TWST is 1 of the 8 higher the last 2 days. $VALN focuses on vaccines which has been a lousy space (of course excluding DVAX). $ORG had finally been running after trading between $6 & $8 a share since Halloween. One has to wonder if OGN under $8 is a memory. OGN generates $6B/year in sales but has a leveraged capital structure. If OGN ever traded at peer multiples...

1 · Reply

RadcliffeRanges Feb. 4 at 9:38 AM

$SUPN specialty pharma, generic competition

0 · Reply

OfficialStocktwitsUser Jan. 30 at 1:18 PM

$SUPN RSI: 32.73, MACD: -0.0402 Vol: 1.02, MA20: 49.98, MA50: 48.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Night_Owl_Biotech Jan. 6 at 12:57 AM

The attachment compares $BCRX revenue multiples (valuation as a multiple of projected revenues) to peer commercial-stage non-oncology focused bios with similar revenue projections. BCRX's gross margins (97% in FY2024) are the highest of all of these peers yet BCRX trades at a meaningfully lower multiple of projected revenues. As we understand it, Orladeyo generics are not to be available until FY2040. $SUPN $TARS trade at meaningfully higher multiples yet are supposed to generate, more or less, the same revenue dollars. $ARQT is projected to generate less revenues $CPRX ? We followed BCRX for years but have not kept up. Any guidance from BCRX bulls would be genuinely appreciated. BCRX is one of the very few commercial-stage non-oncology focused bios not trading meaningfully higher than the XBI lows of early April 2025. We're aware BCRX's enterprise value is roughly $0.05B higher than its market cap. This is not investment advice.

5 · Reply

OfficialStocktwitsUser Jan. 5 at 5:58 PM

$SUPN RSI: 65.21, MACD: 0.8502 Vol: 2.17, MA20: 48.97, MA50: 48.47 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StocktwitsNews Dec. 19 at 6:38 PM

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order $PSIL $SUPN $HELP.DL0126 $ATAI https://stocktwits.com/news/equity/markets/atai-beckley-supernus-jump-as-wall-street-flags-psychedelics-tailwinds-from-trump-marijuana-order/cLe02tNREtb

0 · Reply

Gemola Dec. 19 at 6:24 PM

$SUPN Boolish first target $55.00 ++

0 · Reply

JarvisFlow Dec. 19 at 2:53 PM

Stifel has updated their rating for Supernus Pharmaceuticals ( $SUPN ) to Hold with a price target of 55.

0 · Reply

Market Cap	2.87B
Revenue (ttm)	718.95M
Net Income (ttm)	-38.55M
EPS (ttm)	N/A
PE Ratio	21.99
Forward PE	27.65
Profit Margin	-5.36%
Debt to Equity Ratio	0.00

Volume	549,200
Avg Vol	765,362
Day's Range	N/A - N/A
Shares Out	57.58M
Stochastic %K	28%
Beta	0.70
Analysts	Strong Sell
Price Target	$63.17